{"id":"NCT00701415","sponsor":"Genzyme, a Sanofi Company","briefTitle":"A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms","officialTitle":"A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2008-06-19","resultsPosted":"2016-06-29","lastUpdate":"2016-06-29"},"enrollment":31,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Agalsidase beta","otherNames":["Fabrazyme","Recombinant human α-galactosidase A (r-hαGAL)"]},{"type":"BIOLOGICAL","name":"Agalsidase beta","otherNames":["Fabrazyme","Recombinant human α-galactosidase A (r-hαGAL)"]}],"arms":[{"label":"Fabrazyme 0.5 mg/kg","type":"EXPERIMENTAL"},{"label":"Fabrazyme 1.0 mg/kg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine whether 2 alternative dosing regimens of Fabrazyme (Agalsidase beta) (1.0 mg/kg every 4 weeks or 0.5 mg/kg every 2 weeks) were effective in treatment-naïve pediatric participants without severe symptoms. Participants were to be treated for 5 years.","primaryOutcome":{"measure":"Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium","timeFrame":"Baseline, Week 52, Week 156 and Week 260","effectByArm":[{"arm":"Fabrazyme 0.5 mg/kg","deltaMin":18.8,"sd":null},{"arm":"Fabrazyme 1.0 mg/kg","deltaMin":33.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":12,"countries":["United States","Argentina","Brazil","Canada","Czechia","Netherlands","Norway","Poland","United Kingdom"]},"refs":{"pmids":["25955246","23531228"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":16},"commonTop":["PYREXIA","DIARRHOEA","NAUSEA","VOMITING","ABDOMINAL PAIN"]}}